

Safe Harbor Summary

This presentation includes forward-looking statements that are subject to many risks and uncertainties. These forward-looking statements, such as statements about Amyris's short-term and long-term growth strategies, can sometimes be identified by use of terms such as "intend," "expect," "plan," "estimate," "future," "strive," and similar words. These statements involve many risks and uncertainties that may cause actual results to differ from what may be expressed or implied in these statements. These risks are discussed in our Securities and Exchange Commission filings and reports, including the risks identified under the section captioned "Risk Factors" in our final prospectus relating to its initial public offering filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, on September 28, 2010 and in our quarterly report on Form 10-Q filed on November 10, 2010. We disclaim any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Achievements

- **First Amyris renewable product- Squalane- sold**
- Biomin Biofene™ production starting in April
- Multiple successful runs at industrial scale
- Sao Martinho JV construction remains on plan
- Expanding F&F products (Givaudan)

Outlook

- Strengthening outlook for 2011-2012 production
- Accelerating product introductions
- Targeting ongoing doubling of year on year revenue
- Margin outlook remains on target

Production Outlook

2011-2012 Production

2 Test Run Sites

Biofene Production

Biomin

Tate & Lyle


São Martinho

Plus 1-2 more

Finishing

Glycotech

Production Outlook (Millions of liters)



First Successful Production at Industrial Scale



- Multiple runs in 100,000 and 200,000 liter capacity fermentors
- Contract manufacturing operations in North America and Europe
- Results consistent with previous runs at smaller scale

First Commercial Plant - Biomin





First Commercial Product Produced - Glycotech



Ramping-Up Broader Production



Tate & Lyle - USA



JV São Martinho- Brazil

Building Six Markets to Focus Sales, Drive Growth



Cosmetics



Marketing and Distribution



Flavors and
Fragrances



Development and Supply
Agreements, Profit Sharing



Polymers and
Plastics Additives



Supply Agreement



Consumer
Products
Ingredients



Development and Supply
Agreement



Lubricants



2 Joint Ventures plus Total
Commercial Partnership




Fuels
(Diesel, Jet)



Off-take (Shell) and Joint
Development (Total)

Product Introduction Outlook



Strengthening the Team



Philippe Boisseau,
Director



Paulo Diniz
CEO, Amyris Brasil



Jim Richardson
SVP, Vertical
Markets and Sales
Operations



Joel Velasco
SVP, External
Relations

2011 Outlook: Key Metrics

PRODUCTION VOLUME

6M-9M LITERS

PRODUCTION COST

~\$3.70/LITER

ASP

\$6-\$7/LITER

Non-GAAP OPERATING
EXPENSE*

~\$120M-\$125M

CapEx

~\$75 MILLION

* Our GAAP operating expense outlook includes this \$120M-\$125M non-GAAP forecast plus ~\$20 million stock compensation expense

Key Milestones to Build Value

2011		2012
Add Additional Contract Manuf. Capacity	✓ First Renewable Product Sale – 1H11 (actual: Q1)	Complete SMA Plant Construction – 2Q
Biomin Production Online – 2Q	✓ Additional Supply Agreements - ongoing	Introduce ~6 New Products
✓ Finishing Operations Online – 2Q (actual: Q1)	First Lubricants Sale – 4Q	Execute on Upstream Capacity for 2013
Expanded Contract Manufacturing Online – 3Q		

